<DOC>
	<DOC>NCT03023592</DOC>
	<brief_summary>A single-center, self-control, open-label study of efficacy and safety of Iguratimod in patients with Sjögren's Syndrome</brief_summary>
	<brief_title>Study of Iguratimod in Sjögren's Syndrome</brief_title>
	<detailed_description>In this study, patients with Sjögren's Syndrome are enrolled and received Iguratimod 25 mg twice a day for 24 weeks. The differences of ESSPRI (EULAR Sjogren's Syndrome Patient Reported Index) score, ESSPRI(EULAR Sjogren's Syndrome Patient Reported Index) score, unstimulated salivary flow rate, Schirmer's test SF-36 score and HAQ score between baseline and week 24 are evaluated to determine the efficacy of Iguratimod in patients with Sjögren's Syndrome.</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Sjogren's Syndrome</mesh_term>
	<criteria>A diagnosis of Sjogren's syndrome according to the revised AmericanEuropean Consensus Group (AECG) criteria Positive dry eyes and (or) dry mouth symptoms Hyperglobulinemia Complicated with other systemic autoimmune diseases Severe complications of Sjogren's syndrome Glucocorticosteroid therapy, systemic immunosuppressant therapy, or biological agents therapy within 3 months prior to the screening visit Active infections or chronic infectious diseases A history of malignancies Pregnancy or breathfeeding Inability to comply with the study protocol for any other reason</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Sjogren's Syndrome</keyword>
	<keyword>Iguratimod</keyword>
</DOC>